Novel CHK1 inhibitor MU380 exhibits significant single-agent
activity in TP53-mutated chronic lymphocytic leukemia cells

J 2019

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells

BOUDNÝ, Miroslav, Jana ZEMANOVÁ, PrashantKumar KHIRSARIYA, Marek BORSKÝ, Jan VERNER et. al.

Základní údaje

Originální název

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells

Autoři

BOUDNÝ, Miroslav (203 Česká republika, domácí), Jana ZEMANOVÁ (203 Česká republika, domácí), PrashantKumar KHIRSARIYA (356 Indie, domácí), Marek BORSKÝ (203 Česká republika, domácí), Jan VERNER (203 Česká republika, domácí), Jana ČERNÁ (203 Česká republika, domácí), Alexandra OLTOVÁ (203 Česká republika, domácí), Václav ŠEDA (203 Česká republika, domácí), Marek MRÁZ (203 Česká republika, domácí), Josef JAROŠ (203 Česká republika, domácí), Zuzana JAŠKOVÁ (703 Slovensko, domácí), Michaela ŠPUNAROVÁ (203 Česká republika, domácí), Yvona BRYCHTOVÁ (203 Česká republika, domácí), Karel SOUČEK (203 Česká republika, domácí), Stanislav DRÁPELA (203 Česká republika, domácí), Marie KAŠPÁRKOVÁ (203 Česká republika, domácí), Jiří MAYER (203 Česká republika, domácí), Kamil PARUCH (203 Česká republika, domácí) a Martin TRBUŠEK (203 Česká republika, garant, domácí)

Vydání

Haematologica, PAVIA, FERRATA STORTI FOUNDATION, 2019, 0390-6078

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.116

Kód RIV

RIV/00216224:14110/19:00108541

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3324/haematol.2018.203430

UT WoS

000499687600029

Klíčová slova anglicky

IN-VITRO; KINASE; CLL; PROLIFERATION; ACTIVATION; MUTATIONS; LETHALITY; OUTCOMES; IMPACT; MODEL

Štítky

14110212, 14110517, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 2. 2023 11:57, Mgr. Marie Šípková, DiS.

Anotace

V originále

Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently experience early progression of the disease. Development of alternative therapeutic approaches is, therefore, of critical importance. Here we report details of the anti-chronic lymphocytic leukemia single-agent activity of MU380, our recently identified potent, selective, and metabolically robust inhibitor of checkpoint kinase 1. We also describe a newly developed enantioselective synthesis of MU380, which allows preparation of gram quantities of the substance. Checkpoint kinase 1 is a master regulator of replication operating primarily in intra-S and G(2)/M cell cycle checkpoints. Initially tested in leukemia and lymphoma cell lines, MU380 significantly potentiated efficacy of gemcitabine, a clinically used inducer of replication stress. Moreover, MU380 manifested substantial single-agent activity in both TP53-wild type and TP53-mutated leukemia and lymphoma cell lines. In chronic lymphocytic leukemia-derived cell lines MEC-1, MEC-2 (both TP53-mut), and OSU-CLL (TP53-wt) the inhibitor impaired cell cycle progression and induced apoptosis. In primary clinical samples, MU380 used as a single-agent noticeably reduced the viability of unstimulated chronic lymphocytic leukemia cells as well as those induced to proliferate by anti-CD40/IL-4 stimuli. In both cases, effects were comparable in samples harboring p53 pathway dysfunction (TP53 mutations or ATM mutations) and TP53-wt/ATM-wt cells. Lastly, MU380 also exhibited significant in vivo activity in a xenotransplant mouse model (immunodeficient strain NOD-scid IL2R gamma(null)) where it efficiently suppressed growth of subcutaneous tumors generated from MEC-1 cells.

Návaznosti

LM2015063, projekt VaV

Název: Národní infrastruktura chemické biologie (Akronym: CZ-OPENSCREEN)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZ-OPENSCREEN: National Infrastructure for Chemical Biology

LQ1601, projekt VaV

Název: CEITEC 2020 (Akronym: CEITEC2020)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CEITEC 2020

MUNI/A/1105/2018, interní kód MU

Název: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VI (Akronym: VýDiTeHeMA VI)

Investor: Masarykova univerzita, Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VI, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

NV15-33999A, projekt VaV

Název: Vývoj nových nízkomolekulárních protinádorových léčiv na principu syntetické letality

Citovat

BOUDNÝ, Miroslav, Jana ZEMANOVÁ, PrashantKumar KHIRSARIYA, Marek BORSKÝ, Jan VERNER, Jana ČERNÁ, Alexandra OLTOVÁ, Václav ŠEDA, Marek MRÁZ, Josef JAROŠ, Zuzana JAŠKOVÁ, Michaela ŠPUNAROVÁ, Yvona BRYCHTOVÁ, Karel SOUČEK, Stanislav DRÁPELA, Marie KAŠPÁRKOVÁ, Jiří MAYER, Kamil PARUCH a Martin TRBUŠEK. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. Haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2019, roč. 104, č. 12, s. 2443-2455. ISSN 0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2018.203430.

@article{1582239,
   author = {Boudný, Miroslav and Zemanová, Jana and Khirsariya, PrashantKumar and Borský, Marek and Verner, Jan and Černá, Jana and Oltová, Alexandra and Šeda, Václav and Mráz, Marek and Jaroš, Josef and Jašková, Zuzana and Špunarová, Michaela and Brychtová, Yvona and Souček, Karel and Drápela, Stanislav and Kašpárková, Marie and Mayer, Jiří and Paruch, Kamil and Trbušek, Martin},
   article_location = {PAVIA},
   article_number = {12},
   doi = {http://dx.doi.org/10.3324/haematol.2018.203430},
   keywords = {IN-VITRO; KINASE; CLL; PROLIFERATION; ACTIVATION; MUTATIONS; LETHALITY; OUTCOMES; IMPACT; MODEL},
   language = {eng},
   issn = {0390-6078},
   journal = {Haematologica},
   title = {Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells},
   url = {http://www.haematologica.org/content/104/12/2443},
   volume = {104},
   year = {2019}
}

TY  - JOUR
ID  - 1582239
AU  - Boudný, Miroslav - Zemanová, Jana - Khirsariya, PrashantKumar - Borský, Marek - Verner, Jan - Černá, Jana - Oltová, Alexandra - Šeda, Václav - Mráz, Marek - Jaroš, Josef - Jašková, Zuzana - Špunarová, Michaela - Brychtová, Yvona - Souček, Karel - Drápela, Stanislav - Kašpárková, Marie - Mayer, Jiří - Paruch, Kamil - Trbušek, Martin
PY  - 2019
TI  - Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
JF  - Haematologica
VL  - 104
IS  - 12
SP  - 2443-2455
EP  - 2443-2455
PB  - FERRATA STORTI FOUNDATION
SN  - 03906078
KW  - IN-VITRO
KW  - KINASE
KW  - CLL
KW  - PROLIFERATION
KW  - ACTIVATION
KW  - MUTATIONS
KW  - LETHALITY
KW  - OUTCOMES
KW  - IMPACT
KW  - MODEL
UR  - http://www.haematologica.org/content/104/12/2443
L2  - http://www.haematologica.org/content/104/12/2443
N2  - Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation, and cases with TP53 defects more frequently experience early progression of the disease. Development of alternative therapeutic approaches is, therefore, of critical importance. Here we report details of the anti-chronic lymphocytic leukemia single-agent activity of MU380, our recently identified potent, selective, and metabolically robust inhibitor of checkpoint kinase 1. We also describe a newly developed enantioselective synthesis of MU380, which allows preparation of gram quantities of the substance. Checkpoint kinase 1 is a master regulator of replication operating primarily in intra-S and G(2)/M cell cycle checkpoints. Initially tested in leukemia and lymphoma cell lines, MU380 significantly potentiated efficacy of gemcitabine, a clinically used inducer of replication stress. Moreover, MU380 manifested substantial single-agent activity in both TP53-wild type and TP53-mutated leukemia and lymphoma cell lines. In chronic lymphocytic leukemia-derived cell lines MEC-1, MEC-2 (both TP53-mut), and OSU-CLL (TP53-wt) the inhibitor impaired cell cycle progression and induced apoptosis. In primary clinical samples, MU380 used as a single-agent noticeably reduced the viability of unstimulated chronic lymphocytic leukemia cells as well as those induced to proliferate by anti-CD40/IL-4 stimuli. In both cases, effects were comparable in samples harboring p53 pathway dysfunction (TP53 mutations or ATM mutations) and TP53-wt/ATM-wt cells. Lastly, MU380 also exhibited significant in vivo activity in a xenotransplant mouse model (immunodeficient strain NOD-scid IL2R gamma(null)) where it efficiently suppressed growth of subcutaneous tumors generated from MEC-1 cells.
ER  -

BOUDNÝ, Miroslav, Jana ZEMANOVÁ, PrashantKumar KHIRSARIYA, Marek BORSKÝ, Jan VERNER, Jana ČERNÁ, Alexandra OLTOVÁ, Václav ŠEDA, Marek MRÁZ, Josef JAROŠ, Zuzana JAŠKOVÁ, Michaela ŠPUNAROVÁ, Yvona BRYCHTOVÁ, Karel SOUČEK, Stanislav DRÁPELA, Marie KAŠPÁRKOVÁ, Jiří MAYER, Kamil PARUCH a Martin TRBUŠEK. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. \textit{Haematologica}. PAVIA: FERRATA STORTI FOUNDATION, 2019, roč.~104, č.~12, s.~2443-2455. ISSN~0390-6078. Dostupné z: https://dx.doi.org/10.3324/haematol.2018.203430.

Podrobný výpis o publikaci